Forecast

The analysts' average price target is €57.16 (+53.86%). The median is €54.75 (+47.38%).

Buy	38
Hold	6
Sell	0

News Go to news feed

Cyberattack weighs on Boston Scientific outlook

Boston Scientific says an eight-day cyberattack disrupted global operations and will likely cause it to miss Q3 and full-year 2026 guidance, although IT, sales and manufacturing systems have now been restored. Demand for WATCHMAN remains weak in the near term; U.S. procedures are expected to decline by the mid- to high-single digits in H2 2026, and market share in pulse field ablation (FARAPULSE) has fallen to about 50%. Management expects only minimal EPS growth in 2027 but anticipates a return to more typical growth in 2028, cites several product launches as drivers, and confirms the planned acquisition of Penumbra is on track to close by the end of 2026. » More on de.investing.com
Boston Scientific says cyberattack will prevent meeting 2026 sales and profit forecasts

Boston Scientific said an unauthorized activity on its IT systems first identified on August 25 disrupted manufacturing, sterilization and order processing, and it no longer expects to meet its previously issued third-quarter and full-year 2026 sales and adjusted profit targets. The company has restored major distribution centers and restarted most manufacturing, and expects to recover some lost revenue as it reduces backlogs. The full financial impact remains uncertain and Boston Scientific will provide an update with third-quarter results on October 28. » More on finance.yahoo.com
Boston Scientific's supply chain disrupted worldwide by cyberattack

Boston Scientific reports a cyberattack discovered on August 25 that has affected information systems and business applications, causing disruptions to order processing and shipping worldwide. Employees at one site in Ireland were sent home. The company has brought in external cybersecurity experts and is working on restoration, but cannot say when full operations will resume; the extent of operational and financial damage remains unclear. » More on golem.de

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Boston Scientific has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Boston Scientific had revenue of €4.77bn and net profit of €794.72m

(EUR)	June 2026	YoY
Revenue	4.77bn	11.05%
Gross profit	3.37bn	16.06%
Net profit	794.72m	18.12%
EBITDA	1.22bn	4.94%

Fundamentals

Metric	Value
Market capitalization	€55.23bn
Number of shares	1.49bn
52-week high/low	€91.15 - €36.39
Dividends	No
Beta	0.57
P/E ratio	17.38
PEG ratio	0.38
P/B ratio	2.55
P/S ratio	3.05

Company profile

Die Boston Scientific Corporation entwickelt, produziert und vertreibt weltweit medizinische Geräte für den Einsatz in verschiedenen interventionellen medizinischen Fachgebieten. Das Unternehmen ist in drei Segmenten tätig: MedSurg, Rhythm and Neuro, und Cardiovascular. Das Unternehmen bietet Geräte zur Diagnose und Behandlung von Magen-Darm- und Lungenerkrankungen, Geräte zur Behandlung verschiedener urologischer und pelviner Erkrankungen, implantierbare Kardioverter und implantierbare Herz-Resynchronisations-Therapie-Defibrillatoren, Herzschrittmacher und implantierbare Herz-Resynchronisations-Therapie-Schrittmacher sowie Remote-Patienten-Management-Systeme. Darüber hinaus bietet das Unternehmen Medizintechnologien zur Diagnose und Behandlung von Herzrhythmusstörungen an, darunter 3D-Kardio-Mapping- und Navigationslösungen, Ablationskatheter, Diagnosekatheter, Mapping-Katheter, intrakardiale Ultraschallkatheter, Einführschleusen und anderes Zubehör, Rückenmarkstimulatorsysteme für die Behandlung chronischer Schmerzen, indirekte Dekompressionssysteme und Systeme zur Tiefenhirnstimulation. Darüber hinaus bietet das Unternehmen Produkte für die interventionelle Kardiologie an, darunter medikamentenfreisetzende Koronarstentsysteme zur Behandlung der Koronararterienerkrankung, Produkte für die perkutane Koronarintervention zur Behandlung von Atherosklerose, Katheter für die intravaskuläre Ultraschallbildgebung, Geräte für die fraktionierte Flussreserve und Systeme für den Einsatz in Koronararterien und Herzkammern sowie in verschiedenen peripheren Gefäßen und strukturelle Herztherapien. Darüber hinaus bietet das Unternehmen Stents, Ballonkatheter, Drähte und Atherektomiesysteme zur Behandlung von Arterienerkrankungen, Thrombektomie- und akustische Impulsthrombolysesysteme, Drähte und Stents zur Behandlung von Venenerkrankungen sowie periphere Embolisationsgeräte, radioaktive Mikrosphären, Ablationssysteme, Kryotherapie-Ablationssysteme und Mikro- und Drainagekatheter zur Behandlung von Krebs. Das Unternehmen wurde 1979 gegründet und hat seinen Hauptsitz in Marlborough, Massachusetts.

Name	Boston Scientific
CEO	Michael F. Mahoney
Headquarters	Marlborough, ma USA
Website	bsci.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	19/11/2019
Employees	59,000